Elanco Animal Health develops, manufactures and markets animal health products for farm animals and pets. News about ELAN commonly covers operating and financial results, product launches in pet health and livestock health, and regulatory actions involving animal medicines and parasite-control products.
Company updates also include capital-structure disclosures, investor conference presentations, and governance changes tied to Elanco's board and public-company operations. Product-specific developments have included the Advantage brand for dogs and emergency-authorized livestock treatments such as Negasunt Powder and Tanidil.
Elanco Animal Health (NYSE: ELAN) released consumer research showing 93% of surveyed pet owners maintained or increased pet spending over the past three months. The survey covered 2,018 U.S. consumers, including 1,495 dog and cat owners, and was conducted in mid-October 2026.
Among pet owners surveyed, 32% reported increased spending over the past three months, while 93% expected to maintain or increase spending in the year ahead. Just 7% of surveyed consumers would cut pet health spending under economic pressure, compared with 54% for dining out and entertainment. Across all consumers surveyed, 21% expected to add a pet in the year ahead.
Elanco Animal Health (NYSE: ELAN) reported third-quarter 2026 revenue of $1.265 billion, up year over year, and raised its full-year outlook. Revenue increased 11%, or 9% excluding currency effects, the AHV acquisition and sold royalties and milestones. Reported net income was $18 million, or $0.04 per diluted share, versus a $34 million loss a year earlier. Adjusted EBITDA rose 23% to $243 million.
Pet Health revenue grew 14% to $608 million; Farm Animal revenue rose 6% to $631 million. Net leverage reached 2.9x adjusted EBITDA. Elanco now expects full-year revenue of $5.155 billion to $5.18 billion, excluding sold royalties and milestones, and adjusted EPS of $1.17 to $1.20. It raised its innovation revenue target to $1.275 billion. For 2027, the company continues to expect mid-single-digit organic constant currency revenue growth, high-single-digit adjusted EBITDA growth and low-double-digit adjusted EPS growth.
Elanco Animal Health (NYSE: ELAN) will participate in the UBS Global Healthcare Conference on November 9, 2026, through a fireside chat.
CFO Bob VanHimbergen and Bobby Modi, executive vice president U.S. Pet Health and Global Digital Transformation, will speak at 1:15 p.m. EST. A live audio webcast will be available in the Events and Presentations section of Elanco's investor website, with a replay available for a limited time afterward.
Elanco Animal Health (ELAN) appointed Jamie Preston as Executive Vice President and Chief People Officer, effective November 3, 2026. Preston succeeds Dave Kinard, who intends to retire at year-end and will work with her during the transition. She joins from Eli Lilly and Company, where she most recently served as Vice President of HR, Global Compensation and Workforce Innovation.
Elanco (ELAN) will participate in the BofA Securities Global Healthcare Conference 2026 on September 22, 2026.
President and CEO Jeff Simmons will join a fireside chat at 2:10 p.m. BST (9:10 a.m. EDT). A live audio webcast and a limited-time replay will be accessible via the Events and Presentations section of Elanco's investor website.
Elanco (ELAN) reports that innovation in parasiticide and dermatology products is driving stronger base business, price acceleration and market share gains in 2026, with U.S. Pet Health on track for previously communicated high-single digit to low double-digit revenue growth in the second half of the year.
In the first half of 2026, U.S. and International Pet Health each delivered 9% organic constant currency revenue growth year over year, with reported growth of 9% and 15%, respectively. Elanco cites share gains across all four major U.S. categories—dermatology, parasiticides, osteoarthritis pain and vaccines—and roughly 1,100 additional Credelio Quattro clinics quarter-to-date (July–August). Internationally, dermatology revenue grew 9% in the first half of 2026 and Zenrelia gained 10 share points in Europe. The legacy base portfolio has improved from mid- to high-single digit declines in 2023–2024 to around plus or minus low-single digit levels currently and expected forward.
Elanco Animal Health (ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026. On the same day, the company will host a conference call for investors, media, and the public, starting at 8:00 a.m. Eastern time, with a live webcast and replay available via its investor relations website.
Elanco (ELAN) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.
President and CEO Jeff Simmons, executive vice president and CFO Bob VanHimbergen, and executive vice president U.S. Pet Health and Global Digital Transformation Bobby Modi will join a fireside chat at 2:35 p.m. ET that day. A live audio webcast will be accessible through the “Events and Presentations” section of Elanco’s investor website, with a replay available for a limited time after the event.
Elanco (NYSE: ELAN) announced the on-time completion of a 25,000-square-foot expansion at its Elwood, Kansas manufacturing site, focused on monoclonal antibody (mAb) production. The project represents a $120 million investment and increases production capacity by more than four times.
The facility manufactures Befrena, an anti-IL-31 mAb for canine allergic and atopic dermatitis, and Trutect, a therapeutic for canine parvovirus. Elanco reported Befrena demand at twice expectations and expects unconstrained supply in early 2027. The expansion adds a pilot plant, quality control lab and support spaces, with an additional $30 million investment planned through 2028, including new warehousing.
Elanco (NYSE: ELAN) announced that the U.S. FDA has granted an Emergency Use Authorization (EUA) for CLiK Extra (dicyclanil topical suspension) wound spray to prevent New World screwworm larvae infestations on or around wounds in sheep, cattle, goats, swine, camelids, and specified captive and captured wildlife, including cervids, American bison, bighorn sheep and Sonoran pronghorn.
According to Elanco, CLiK Extra is for prevention only and does not treat active infestations, has an 86‑day slaughter/harvest restriction for several species, and cannot be used in animals producing milk for human consumption. Elanco also highlights separate emergency authorizations and safety restrictions for Negasunt Powder and Tanidil, plus availability of EPA‑registered Catron IV.